<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatitis viruses and the newborn: Clinical manifestations and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatitis viruses and the newborn: Clinical manifestations and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatitis viruses and the newborn: Clinical manifestations and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donough J O'Donovan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth B Rand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal infections with the hepatotropic viruses are usually the result of vertical transmission from infected mothers. The risk of perinatally or neonatal-acquired infection and its clinical manifestations and implications vary depending on the hepatotropic virus and are reviewed here.
        </p>
        <p>
         Prevention, diagnosis, and management of hepatitis viruses in older infants, children, and adolescents are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5942.html" rel="external">
          "Overview of hepatitis A virus infection in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">
          "Hepatitis B virus immunization in infants, children, and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">
          "Hepatitis C virus infection in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HEPATITIS A
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis A virus (HAV) is a nonenveloped 27-nm RNA virus that is a member of the Picornaviridae family. The virus is transmitted by person-to-person contact through fecal-oral contamination. The infection is highly contagious, and epidemics frequently result from common exposure to contaminated food and water. (See
         <a class="medical medical_review" href="/z/d/html/5942.html" rel="external">
          "Overview of hepatitis A virus infection in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2692.html" rel="external">
          "Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361890862">
         <span class="h2">
          Transmission
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal vertical transmission
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intrauterine
         </strong>
         – Intrauterine transmission of HAV is rare, described in isolated case reports of intrauterine transmission of HAV in early pregnancy [
         <a href="#rid1">
          1,2
         </a>
         ]. These cases presented with fetal ascites and meconium peritonitis. After birth, serologic testing confirmed HAV infection in both infants who required surgical intervention for meconium peritonitis. Their subsequent recovery was uneventful.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Perinatal
         </strong>
         – The risk of perinatal transmission is low. Despite the widespread global distribution of HAV infection, only a few case reports describe vertical transmission of HAV during the weeks before or at birth [
         <a href="#rid3">
          3-5
         </a>
         ]. For most of these infants, vertical transmission was identified when the infant presented with hepatitis during the newborn period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There is no evidence that hepatitis A is transmitted through breast milk [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired neonatal disease
         </strong>
         – Neonatal-acquired HAV infection is rare. There are reported neonatal cases of HAV due to transfusion of contaminated blood or fresh frozen plasma [
         <a href="#rid7">
          7-9
         </a>
         ] and horizontal transmission from healthcare personnel [
         <a href="#rid3">
          3,8
         </a>
         ]. In an outbreak in a neonatal intensive care unit in Hawaii, 13 infants, 22 nurses, 8 other staff, and 4 household contacts were identified with HAV infection [
         <a href="#rid8">
          8
         </a>
         ]. Two infants, who received blood transfusions from a donor with HAV infection, were identified as the primary cases and served as a common source of infection for the other infants and staff.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Clinical manifestations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In utero
         </strong>
         – For the most part, HAV infection is self-limiting in pregnant women. Although maternal HAV infection does not appear to increase the risk of congenital malformations, intrauterine growth restriction, spontaneous abortion or stillbirth [
         <a href="#rid10">
          10,11
         </a>
         ], there is an increased risk of preterm labor and premature rupture of membranes. (See
         <a class="medical medical_review" href="/z/d/html/3564.html" rel="external">
          "Overview of coincident acute hepatobiliary disease in pregnant women", section on 'Hepatitis A virus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In the newborn
         </strong>
         – Most newborn infants with HAV infection are asymptomatic, but symptomatic cases have been reported [
         <a href="#rid4">
          4,12,13
         </a>
         ]. In one case series of six infants ranging from two weeks to eight months old, all of the patients presented with loss of appetite and jaundice and in four patients, elevated temperature and recurrent vomiting were also observed [
         <a href="#rid12">
          12
         </a>
         ]. During the course of the disease, all six infants developed hepatomegaly and biochemical evidence of mild hepatitis. All infants had complete clinical and biochemical recovery three months after the acute disease with no long-term sequelae. Other reports have documented similar clinical findings in newborn infants infected with HAV [
         <a href="#rid4">
          4,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fulminant hepatitis resulting from infection with HAV is rare in children and, to our knowledge, has not been reported in the newborn infant. (See
         <a class="medical medical_review" href="/z/d/html/5942.html" rel="external">
          "Overview of hepatitis A virus infection in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Prevention and treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infant of a mother with active HAV infection
         </strong>
         – For infants born to mothers with HAV symptoms in the perinatal period (two weeks before to one week after birth), some experts advise giving immune serum globulin (0.02 mL/kg intramuscularly) to the infant [
         <a href="#rid14">
          14
         </a>
         ]. However, the efficacy of immune serum globulin in these circumstances has not been fully established, and immunoprophylaxis may be less effective in newborn infants than in older children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of an infected infant
         </strong>
         – The treatment for newborn infants with HAV infection is supportive. Strict attention to infection control is necessary because HAV-positive infants are infectious for many months [
         <a href="#rid8">
          8
         </a>
         ]. Measures include strict handwashing by caregivers and ensuring that all caregivers and household contacts are fully immunized. HAV-infected mothers may continue to breastfeed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Universal immunization
         </strong>
         – In the United States, immunization with an inactivated
         <a class="drug drug_pediatric" data-topicid="12935" href="/z/d/drug information/12935.html" rel="external">
          hepatitis A vaccine
         </a>
         is recommended for all children beginning at one year of age [
         <a href="#rid14">
          14
         </a>
         ]. Vaccination of infants six months or older is recommended for those traveling to endemic areas. In endemic areas, newborn and premature infants born to seronegative mothers are potentially at risk and may benefit from early immunization with HAV vaccines [
         <a href="#rid12">
          12,15
         </a>
         ]. However, vaccination trials in these patient populations are warranted before routine early immunization with HAV vaccines can be recommended. (See
         <a class="medical medical_review" href="/z/d/html/5942.html" rel="external">
          "Overview of hepatitis A virus infection in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3900.html" rel="external">
          "Hepatitis A virus infection: Treatment and prevention", section on 'Protection prior to exposure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          HEPATITIS B
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis B virus (HBV) is an enveloped DNA virus that is a member of the Hepadnaviridae family.
        </p>
        <p class="headingAnchor" id="H361891272">
         <span class="h2">
          Transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal infection is a result of perinatal exposure from an HBV-infected mother. The infection rate among exposed infants with infected mothers who do not receive any form of prophylaxis is as high as 90 percent. Perinatal transmission, including risk factors and preventive measures, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Effect of chronic HBV on pregnancy outcomes'
         </a>
         .)
        </p>
        <p>
         Breastfeeding by an HBV-infected mother is not contraindicated, as it does not increase the risk of transmission. Infants who received
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         (HBIG) and the first dose of vaccine at birth can be breastfed as long as they complete the course of vaccination. Mothers with HBV should not participate in donating breast milk. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Breastfeeding and transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Clinical manifestations and course
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newborn infants with HBV infection rarely show clinical or biochemical signs of disease at birth. Most affected newborns remain asymptomatic and develop chronic antigenemia with mild and often persistent liver enzyme elevations beginning at two to six months of age. This is known as the immune-tolerant phase of HBV infection, which can persist for years or even decades or progress to the immune-active phase  (
         <a class="graphic graphic_figure graphicRef64996" href="/z/d/graphic/64996.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid10">
          10,16,17
         </a>
         ]. A small number of infants will develop acute hepatitis by two months of age and present with icteric and, occasionally, fulminant hepatitis [
         <a href="#rid17">
          17-20
         </a>
         ]. Others may develop chronic liver disease later in life, with risks for cirrhosis and/or hepatocellular carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents", section on 'Chronic hepatitis B virus infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361892037">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HBV infection is based on serologic assays that identify the presence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and antibodies to these viral proteins  (
         <a class="graphic graphic_table graphicRef60627" href="/z/d/graphic/60627.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef69344" href="/z/d/graphic/69344.html" rel="external">
          figure 2
         </a>
         ). The presence of HBsAg in the infant after one to two months of age indicates vertically acquired HBV infection. HBsAg may be transiently positive in neonates up to 21 days following hepatitis B vaccination [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults", section on 'Diagnostic algorithms'
         </a>
         .)
        </p>
        <p>
         Testing for HBV DNA is not recommended for screening, because this test may remain positive for months or years after clearance of HBV infection. (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults", section on 'Serum HBV DNA assays'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Mother-to-child transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important strategies to prevent HBV infection in children are universal HBV immunization for all infants and the combination of immunoprophylaxis (HBIG) and HBV immunization for infants born to HBsAg-positive mothers.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Universal immunization
         </strong>
         – Universal HBV immunization is recommended for all infants. The optimal intervals and need for HBIG are determined by the mother's HBsAg status and the infant's birth weight. (See
         <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">
          "Hepatitis B virus immunization in infants, children, and adolescents", section on 'Routine infant immunization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infant of an HBsAg-positive mother
         </strong>
         – Infants of HBsAg-positive mothers should receive monovalent hepatitis B vaccine and HBIG 0.5 mL as soon after birth as possible (preferably within 12 hours), regardless of birth weight. The schedule for subsequent doses of hepatitis B vaccine depends upon the infant's birth weight  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         ). This combination of passive and active immunization dramatically reduces the rate of perinatally-acquired HBV from an infected mother. These and other recommendations for immunoprophylaxis and post-vaccination testing are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">
          "Hepatitis B virus immunization in infants, children, and adolescents", section on 'HBsAg-positive mother or mother with other evidence of HBV infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H361892044">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific therapy is generally warranted for infants and children with vertically transmitted HBV, as most patients are asymptomatic through infancy and childhood with consistently normal alanine aminotransferase (ALT) values (immune-tolerant). Management for most patients usually involves monitoring for disease progression by laboratory evaluation that includes liver enzyme testing and HBV serology  (
         <a class="graphic graphic_figure graphicRef64996" href="/z/d/graphic/64996.html" rel="external">
          figure 1
         </a>
         ). Although several treatment options are available for children two years or older, these are typically ineffective in children in the immune-tolerant phase. As a result, the decision to treat is based on individual patient factors, which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents", section on 'Selection of patients for antiviral treatment'
         </a>
         .)
        </p>
        <p>
         For the very rare case of an infant with acute and fulminant HBV infection, off-label use of nucleos(t)ide analogs may be warranted. (See
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents", section on 'Nucleos(t)ide analogs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          HEPATITIS C
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis C virus (HCV) is a small, single-stranded, enveloped RNA virus that is a member of the Flaviviridae family.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission
         </strong>
         – Vertical transmission is the primary source of pediatric infection. The risk of transmitting the virus from an HCV-infected woman to her infant is approximately 5 percent but is higher if the mother is coinfected with human immunodeficiency virus (HIV). Horizontal transmission (child-to-child or adult-to-child) transmission of HCV in the neonatal period is rare. Breastfeeding is not contraindicated. (See
         <a class="medical medical_review" href="/z/d/html/3637.html" rel="external">
          "Vertical transmission of hepatitis C virus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Newborn infants with HCV infection usually are asymptomatic, and most have normal or only mildly elevated serum alanine aminotransferase (ALT) concentrations. Although a majority of infants with vertically acquired HCV develop chronic infection, liver disease usually is mild throughout childhood. (See
         <a class="medical medical_review" href="/z/d/html/3637.html" rel="external">
          "Vertical transmission of hepatitis C virus", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HCV is made by detecting antibodies to HCV. However, antibody testing of infants of women known to be infected with HCV should be delayed until the maternal antibodies transferred through the placenta are cleared and will no longer confound the results of serologic testing [
         <a href="#rid22">
          22
         </a>
         ]. This typically takes at least 12 to 18 months. (See
         <a class="medical medical_review" href="/z/d/html/3637.html" rel="external">
          "Vertical transmission of hepatitis C virus", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – The best strategy for reducing the risk of vertical HCV transmission is to identify and treat HCV-infected women prior to conception, using direct-acting antiviral agents. These drugs should not be given during pregnancy, because their safety and efficacy for preventing perinatal transmission have not been evaluated. (See
         <a class="medical medical_review" href="/z/d/html/3637.html" rel="external">
          "Vertical transmission of hepatitis C virus", section on 'Screening and prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Treatment of children with perinatally acquired HCV is generally recommended after three years of age, using a direct-acting antiviral agent. The decision to treat and options are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">
          "Hepatitis C virus infection in children", section on 'Management of chronic hepatitis C virus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H361893731">
         <span class="h1">
          OTHER HEPATOTROPIC VIRUSES
         </span>
        </p>
        <p class="headingAnchor" id="H361893422">
         <span class="h2">
          Hepatitis D
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis D virus (HDV) is an RNA virus, the replication of which requires hepatitis B virus (HBV) as a helper virus. Infection occurs only in persons who are hepatitis B surface antigen (HBsAg)-positive, either as a coinfection (simultaneous infection with HBV and HDV) or as a superinfection (infection of a chronic HBV carrier with HDV).
        </p>
        <p>
         Vertical transmission of HDV has been documented but is uncommon. Therapeutic strategies designed to prevent perinatal acquisition of HBV in infants born to HBsAg-positive mothers are also effective in preventing the transmission of HDV [
         <a href="#rid23">
          23
         </a>
         ]. Because HDV cannot be transmitted in the absence of HBV, routine immunization of all newborn infants with the hepatitis B vaccine protects against HDV. (See
         <a class="medical medical_review" href="/z/d/html/3666.html" rel="external">
          "Epidemiology, clinical manifestations and diagnosis of hepatitis D virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3664.html" rel="external">
          "Treatment and prevention of hepatitis D virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Hepatitis E
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis E virus (HEV) is a single-stranded RNA virus that is structurally similar to a calicivirus [
         <a href="#rid24">
          24
         </a>
         ]. Infection with HEV usually causes a self-limiting acute hepatitis similar to hepatitis A virus (HAV), although fulminant hepatitis can occur. The virus is transmitted by the fecal-oral route. HEV infection is rare in the United States but endemic in many resource-limited countries. (See
         <a class="medical medical_review" href="/z/d/html/3677.html" rel="external">
          "Hepatitis E virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertical transmission and clinical manifestations
         </strong>
         – Although information regarding perinatal transmission is limited, several case series describe vertical transmission of HEV. Infants presented with signs of hepatitis, including jaundice, hyperbilirubinemia, elevated serum alanine aminotransferase (ALT) levels; hypothermia, and hypoglycemia [
         <a href="#rid25">
          25-28
         </a>
         ]. HEV infection in survivors was usually self-limited with short-lasting viremia, but cases of severe illness, including massive hepatic necrosis and death, have been reported [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HEV infection is based upon the detection of HEV in serum or stool by polymerase chain reaction (PCR) or by the detection of IgM antibodies to HEV. (See
         <a class="medical medical_review" href="/z/d/html/3677.html" rel="external">
          "Hepatitis E virus infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Supportive care is the only available treatment as specific treatments for infected infants do not exist.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3084319760">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116507.html" rel="external">
          "Society guideline links: Pediatric liver disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361893725">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatitis A
         </strong>
         (see
         <a class="local">
          'Hepatitis A'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transmission
         </strong>
         – The risk of vertical transmission of hepatitis A virus (HAV) from an infected mother is small. Neonatal-acquired HAV infection is also uncommon and is primarily due to transfusion of contaminated blood products and horizontal transmission from infected health care workers. (See
         <a class="local">
          'Transmission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Most newborn infants with HAV infection are asymptomatic, and those who are symptomatic generally have mild hepatitis manifested by poor feeding and jaundice. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention and treatment
         </strong>
         – For infants born to mothers with HAV symptoms in the perinatal period (two weeks before to one week after birth), some experts advise giving immune serum globulin (0.02 mL/kg intramuscularly) to the infant. Treatment of neonatal HAV infection is supportive, and the infection self-resolves. (See
         <a class="local">
          'Prevention and treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatitis B
         </strong>
         (see
         <a class="local">
          'Hepatitis B'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transmission
         </strong>
         – The risk of vertical transmission of hepatitis B virus (HBV) is as high as 90 percent for infants born to mothers with HBV infection unless the infant is given immunoprophylaxis at birth. (See
         <a class="local">
          'Transmission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical manifestations and diagnosis
         </strong>
         – Newborn infants with HBV infection are usually asymptomatic and rarely show clinical or biochemical signs of disease at birth. However, neonates with HBV infection are at risk to develop chronic infection, which may progress to cirrhosis and/or hepatocellular carcinoma. In infants, the diagnosis of HBV infection is most commonly made by the presence of hepatitis B surface antigen (HBsAg) after one or two months of age  (
         <a class="graphic graphic_table graphicRef60627" href="/z/d/graphic/60627.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations and course'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention
         </strong>
         – Infants of HBsAg-positive mothers should receive monovalent hepatitis B vaccine and HBIG 0.5 mL as soon after birth as possible (preferably within 12 hours), regardless of birth weight. The schedule for subsequent doses of hepatitis B vaccine depends upon the infant's birth weight  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         ). All infants should receive the hepatitis B vaccine as part of the routine childhood immunization program. (See
         <a class="local">
          'Prevention'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">
          "Hepatitis B virus immunization in infants, children, and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – No specific therapy is generally warranted for the majority of patients with vertically transmitted HBV, as they remain asymptomatic through childhood with normal alanine aminotransferase (ALT) values (immune-tolerant). Management for most patients usually only involves monitoring for disease progression by laboratory evaluation that includes liver enzyme testing and HBV serology  (
         <a class="graphic graphic_figure graphicRef64996" href="/z/d/graphic/64996.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatitis C
         </strong>
         (see
         <a class="local">
          'Hepatitis C'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transmission, prevention, clinical manifestations and diagnosis
         </strong>
         – The risk of vertical transmission of hepatitis C virus (HCV) from an infected woman to her infant is approximately 5 percent, which increases if the mother is coinfected with HIV. The best strategy for reducing the risk of vertical HCV transmission is to identify and treat HCV-infected women prior to conception. Newborn infants with HCV infection usually are asymptomatic, and a majority will develop chronic infection. (See
         <a class="medical medical_review" href="/z/d/html/3637.html" rel="external">
          "Vertical transmission of hepatitis C virus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – Treatment of children with perinatally acquired HCV is generally recommended after three years of age, using a direct-acting antiviral agent. The decision to treat and options are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">
          "Hepatitis C virus infection in children", section on 'Management of chronic hepatitis C virus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other hepatitis viruses
         </strong>
         – Vertical transmission of hepatitis D virus (HDV) and hepatitis E virus (HEV) appears to be uncommon. Because HDV cannot be transmitted in the absence of HBV, routine immunization of all newborn infants with the hepatitis B vaccine protects against HDV. (See
         <a class="local">
          'Other hepatotropic viruses'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. Obstet Gynecol 1996; 88:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDuffie RS Jr, Bader T. Fetal meconium peritonitis after maternal hepatitis A. Am J Obstet Gynecol 1999; 180:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson JC, Fleming DW, Borella AJ, et al. Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis 1993; 167:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erkan T, Kutlu T, Cullu F, Tümay GT. A case of vertical transmission of hepatitis A virus infection. Acta Paediatr 1998; 87:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka I, Shima M, Kubota Y, et al. Vertical transmission of hepatitis A virus. Lancet 1995; 345:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daudi N, Shouval D, Stein-Zamir C, Ackerman Z. Breastmilk hepatitis A virus RNA in nursing mothers with acute hepatitis A virus infection. Breastfeed Med 2012; 7:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble RC, Kane MA, Reeves SA, Roeckel I. Posttransfusion hepatitis A in a neonatal intensive care unit. JAMA 1984; 252:2711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991; 164:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KK, Vargo LR, Lê CT, Fernando L. Transfusion-acquired hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit. Pediatr Infect Dis J 1992; 11:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong MJ, Thursby M, Rakela J, et al. Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology 1981; 80:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang RL, Zeng JS, Zhang HZ. Survey of 34 pregnant women with hepatitis A and their neonates. Chin Med J (Engl) 1990; 103:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder N, Karetnyi YV, Kuint J, et al. Symptomatic hepatitis A virus infection during the first year of life. Pediatr Infect Dis J 1995; 14:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagan EA, Hadzic N, Saxena R, Mieli-Vergani G. Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero. Pediatr Infect Dis J 1999; 18:389.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Hepatitis A. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.373.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder N, Karetnyi Y, Gidony Y, et al. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection 1999; 27:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulligan MJ, Stiehm ER. Neonatal hepatitis B infection: clinical and immunologic considerations. J Perinatol 1994; 14:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moroni GA, Chiccoli C, Zanetti AR, et al. Acute hepatitis B in infants born to HBsAG asymptomatic carrier mothers. Acta Paediatr Scand 1982; 71:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinatra FR, Shah P, Weissman JY, et al. Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers. Pediatrics 1982; 70:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaplane D, Yogev R, Crussi F, Shulman ST. Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics 1983; 72:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiraki K, Yoshihara N, Sakurai M, et al. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr 1980; 97:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köksal N, Altinkaya N, Perk Y. Transient hepatitis B surface antigenemia after neonatal hepatitis B immunization. Acta Paediatr 1996; 85:1501.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Hepatitis C. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.399.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison TJ. Hepatitis E virus -- an update. Liver 1999; 19:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khuroo MS, Kamili S, Jameel S. Vertical transmission of hepatitis E virus. Lancet 1995; 345:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar RM, Uduman S, Rana S, et al. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol 2001; 100:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khuroo MS, Kamili S, Khuroo MS. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. J Viral Hepat 2009; 16:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma S, Kumar A, Kar P, et al. Risk factors for vertical transmission of hepatitis E virus infection. J Viral Hepat 2017; 24:1067.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4958 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8841254" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Intrauterine transmission of hepatitis A virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10203675" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Fetal meconium peritonitis after maternal hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440928" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764900" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A case of vertical transmission of hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7845152" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Vertical transmission of hepatitis A virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22537111" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Breastmilk hepatitis A virus RNA in nursing mothers with acute hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6492349" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Posttransfusion hepatitis A in a neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1651359" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1741182" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Transfusion-acquired hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7202982" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Studies on the maternal-infant transmission of the viruses which cause acute hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1698588" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Survey of 34 pregnant women with hepatitis A and their neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7567297" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Symptomatic hepatitis A virus infection during the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223700" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223700" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219645" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8169673" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Neonatal hepatitis B infection: clinical and immunologic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7136606" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute hepatitis B in infants born to HBsAG asymptomatic carrier mothers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7122153" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6683400" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7431166" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9001667" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Transient hepatitis B surface antigenemia after neonatal hepatitis B immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9001667" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Transient hepatitis B surface antigenemia after neonatal hepatitis B immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8988900" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Vaccines to prevent viral hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10395034" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hepatitis E virus -- an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723501" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vertical transmission of hepatitis E virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11728649" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228284" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28570034" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Risk factors for vertical transmission of hepatitis E virus infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
